Episode 065: Breast Cancer Series, Pt. 10-ER+, Metastatic Breast Cancer
The Fellow on Call: The Heme/Onc Podcast
00:00
Second-line Targeted Options and Oral CERDs
Options after progression: switch to CERD (fulvestrant/elacestrant for ESR1 mutations), test for PIK3CA (alpelisib) or consider mTOR inhibition, and PARP for BRCA-mutated disease.
Play episode from 19:54
Transcript
